Bio Green Med Solution, Inc. (BGMS)

Nasdaq: BGMS · Pharmaceutical Preparations · Berkeley Heights, NJ · filing with the SEC since 2000

Full chart Alerts Compare

Grade4.3

◀ Past 4.1● Present 3.3▶ Future 5.2

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Bio Green Med Solution, Inc.

Nine metrics read from its own filings, by tense

Headline grade

4.3/10

◀ Past4.125% of the headline

● Present3.335% of the headline

▶ Future5.240% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.1/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.1/10

Has it survived what it has been through?

21 warning events since 2017; the latest 2026-11-04.

weight 22% of this tense · 2nd percentile among 497 sector filers · read for itself

From the record

Bio Green Med Solution, Inc.'s filings since 2017 show 21 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 15 times, the latest 2026-11-04); a warning not to rely on past financial statements (8-K item 4.02, the latest 2023-11-15); an auditor change (8-K item 4.01, 3 times, the latest 2025-08-28); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2025-03-31) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

1.8/10

What has it actually done, year after year?

8 filed years; profitable in 0 of 9.

weight 45% of this tense · 18th percentile among 323 sector filers · read for its customers

From the record

Bio Green Med Solution, Inc.'s 8 filed years say what it did: it rose in 1 of 3 years; the deepest fall was 100% from fiscal 2018 to fiscal 2020; net income was positive in 0 of 9 of those years (its annual reports).

What it rests on

the share of years revenue rosebottom 17% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak100.0%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

9.9/10

How has it treated the people who own it?

SI estimate 9.9/10, confidence 35 of 100 (one part).

weight 33% of this tense · 99th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 1% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Bio Green Med Solution, Inc.'s shareholder treatment is put at 9.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 1% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.3/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

4.3/10

Is it financially healthy right now?

ROE -44%: lost 44¢ per shareholder dollar. Leverage 16%: owes 16¢ per asset dollar.

weight 45% of this tense · 43rd percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Bio Green Med Solution, Inc. lost about 44 cents for every dollar of shareholders' money. Leverage: it owed about 16 cents per dollar of assets, and net share issuance: its share count grew 9692.4% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 26% of its family
return on equitytop 45% of its family
the share count against the year beforebottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

3.0/10

How strong is its position in its industry?

bottom 30% of 315 in its family; net margin -401.3%.

weight 22% of this tense · 30th percentile among 315 sector filers · read for its customers

From the record

Bio Green Med Solution, Inc.'s standing among 315 graded names in its industry family: revenue of $747 thousand in fiscal 2025 ranks in the bottom 19% by size; a net margin of -401.3% ranks in the bottom 40% (its annual reports).

What it rests on

revenue against the family$747,000bottom 19% of its family
net margin-401.3%bottom 40% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

2.1/10

What are the people in charge doing?

SI estimate 2.1/10, confidence 35 of 100 (one part).

weight 33% of this tense · 21st percentile among 415 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the chief executive's years under the title, which ranks in the bottom 21% of 415 in its family; fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
What the record cannot read: Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
How it was reasoned: one part: the chief executive's years on the record, the one part on file, ranked among 415 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Bio Green Med Solution, Inc.'s leadership is put at 2.1 of 10 with a confidence of 35 of 100, because read from one part only, the chief executive's years under the title, which ranks in the bottom 21% of 415 in its family; fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.2/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed

4.8/10

How much room does it have to grow?

bottom 48% of 273 in its family for room to expand.

weight 33% of this tense · 48th percentile among 273 sector filers · read for itself

From the record

Bio Green Med Solution, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $4 million against no long-term debt tagged leaves 42.8% of its assets as net cash, top 37% of its family; cash from operations less capital spending is -638.6% of revenue (bottom 31%); research spending of 113.5% of revenue (top 49%) (its annual report).

What it rests on

cash less debt against assets42.8%top 37% of its family
cash from operations less capital spending against revenue-638.6%bottom 31% of its family
research spending against revenue113.5%top 49% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

3.7/10

What could actually drive growth from here?

bottom 37% of 306 in its family for growth drivers.

weight 45% of this tense · 37th percentile among 306 sector filers · read for its customers

From the record

Bio Green Med Solution, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 1640.6% (top 2%); research spending grew -65.3% a year (bottom 1%); capital spending grew -60.3% a year (bottom 13%) (its annual reports). Bio Green Med Solution, Inc. reported 4 product lines in fiscal 2025: Fire Safety Equipment at $603 thousand (81%), Safety Aparel at $119 thousand (16%), Project Supply and Installation at $20 thousand (3%), and 1 more (its annual report).

What it rests on

the newest year's revenue growth1640.6%top 2% of its family
three-year growth of research spending-65.3%bottom 1% of its family
three-year growth of capital spending-60.3%bottom 13% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

8.8/10

Did its newest year beat what its own record pointed to?

top 12% of 233 in its family for expectations against reality.

weight 22% of this tense · 88th percentile among 233 sector filers · read for its shareholders

From the record

Bio Green Med Solution, Inc.'s newest year against its own record: net income of $3 million against a prior three-year average of $18 million (top 20%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 5%) (its annual reports).

What it rests on

net income against the prior three years' average+84%top 20% of its family
net margin against its prior averageup more than 100 pointstop 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton BGMS · research, not advice